Peter Jüni

Economics and Econometrics · 2001–2022

A researcher in the Science corpus: 35 papers; trusts 4 researchers and is trusted by 17 researchers here, as inferred from the citation graph.

Subfields

Economics and Econometrics — 72 citations into it; #23,039 of 23,481 by trust here, #1,427 by citations
Statistics and Probability — 61 citations into it; #2,648 of 12,932 by trust here, #289 by citations

Whom Peter Jüni trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

Who trusts Peter Jüni overall

Papers from Peter Jüni's perspective

Ordered by how strongly the researchers Peter Jüni trusts endorse each paper. Same corpus, a different order for every researcher.

How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias (PLoS ONE)
Systematic Review and Meta-analysis Supplements for Primary and Secondary Prevention: Mortality in Randomized Trials of Antioxidant
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (British medical journal)
Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. (Health Technology Assessment)
Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. (New England Journal of Medicine)
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease (Epidemiology)
Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. (American Journal of Epidemiology)
Quantifying heterogeneity in a meta‐analysis (Statistics in Medicine)
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. (New England Journal of Medicine)

Their papers

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study (2008) — 2,397 citations
How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. (2003) — 1,067 citations
Systematic reviews in health care: Assessing the quality of controlled clinical trials. (2001) — 2,907 citations
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions (2016) — 17,786 citations
Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials (2012) — 1,002 citations
Direction and impact of language bias in meta-analyses of controlled trials: empirical study. (2002) — 865 citations
RoB 2: a revised tool for assessing risk of bias in randomised trials (2019) — 28,662 citations
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. (2019) — 3,193 citations
2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). (2022) — 776 citations
2021 ESC/EACTS Guidelines for the management of valvular heart disease. (2021) — 4,456 citations
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. (2020) — 4,117 citations
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. (2020) — 2,055 citations
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019) — 4,665 citations
2018 ESC/EACTS Guidelines on myocardial revascularization. (2019) — 1,295 citations
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. (2019) — 3,945 citations
Five‐Year Outcomes with PCI Guided by Fractional Flow Reserve (2018) — 696 citations
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. (2018) — 1,696 citations
2018 ESC/EACTS Guidelines on myocardial revascularization. (2018) — 4,835 citations
2018 ESC/EACTS Guidelines on myocardial revascularization. (2018) — 1,739 citations
[2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018) — 1,352 citations